Drug Profile
MPI 5019
Latest Information Update: 15 Aug 2007
Price :
$50
*
At a glance
- Originator Chiron Corporation
- Class Antineoplastics; Camptothecins
- Mechanism of Action DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 13 Jun 2001 No-Development-Reported for Solid tumours in USA (Intratumoural)
- 06 Jan 1999 Suspended-Preclinical for Solid tumours in USA (Intratumoural)
- 10 May 1996 Preclinical development for Solid tumours in USA (Intratumoural)